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Abstract 
Background: There are differences of opinion about the beneficial or detrimental effects of opium consumption on 
cardiovascular diseases (CVDs). So, we aimed to study the association between opium use and CVDs.
Methods: We used data obtained from the Rafsanjan Cohort Study (RCS), as a part of the prospective epidemiologi‑
cal research studies in IrAN (PERSIAN), with detailed, validated data on opium consumption and some other expo‑
sures. A total of 10,000 adults were enrolled in the study. Logistic regression models were used to assess the possible 
relationships of opium consumption with the prevalence of ischemic heart diseases (IHD) and myocardial infarction 
(MI).
Results: In this study, 9990 participants in the baseline phase of the Rafsanjan adult cohort study were included 
according to their completed questionnaire. Among all participants, 870 and 296 individuals were found to suffer 
from IHD and MI, respectively. Opium consumption was found to be relatively high in the RCS participants, espe‑
cially in men (men = 2150 and women = 228). Opium use was associated with a higher odds of IHD and MI, with the 
adjusted odds ratios (95% CI) of 1.51 (1.22–1.86) and 1.79 (1.31–2.45), respectively. Also, dose‑response increases were 
observed with the highest odds ratios in the 4th quartile for MI and IHD (p‑values for trend < 0.001). Increased odds 
were observed for the two main methods of opium consumption, i.e. oral and smoking, but oral administration had 
higher odds ratio.
Conclusions: Opium consumption is associated with the increased odds of both IHD and MI diseases.
Keywords: Ischemic heart diseases, Myocardial infarction, Opium use, Prospective epidemiological research studies 
in IrAN (PERSIAN)
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Opium addiction is common in many countries globally. 
This problem is more common in Middle Eastern coun-
tries, especially Pakistan, Afghanistan, and Iran [1, 2]. 
In 2018, the United Nations Office of Drugs and Crime 
(UNODC) estimated that 53 million people of the world 
population (5.5%) aged between 15 and 64, had con-
sumed drugs in the previous year [3, 4] and 585,000 peo-
ple died as a result of drug use in 2017 [4]. Opium, along 
with its derivatives, is the most common drug abused in 
Iran [5]. In recent years, few cases on lead poisoning due 
to opium consumption in Iran have been reported [6]. 
Additionally, some researchers reported the contamina-
tion of opium with lead in the southeast of Iran [7, 8]. 
This toxic substance exists as an impurity and adulterant 
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in the illicit opium distributed in Iran. Lead has severe 
effects on human health [9].
Prevalence of cardiovascular diseases (CVDs) showed 
an increase in recent years [10]. It has been reported 
that CVDs are the cause of 50% of deaths in developed 
countries and 25% of deaths in developing countries 
[11]. According to the report of World Health Organiza-
tion (WHO), CVDs cause one third of all annual deaths 
worldwide [12]. For a long time, it was believed that 
opium use can prevent the traditional risk factors of 
CVDs and equilibrate metabolic systems [13]. Particu-
larly, some of healthcare incumbents and even physicians 
conceived that opium consumption has a preventive role 
on insulin resistance, diabetes mellitus, and lipid profile 
disturbances [14]. For instance, according to a large clini-
cal survey in 2015, around 5.2% of the Iranian patients 
that suffered from CVDs were opium-dependent [15]. 
It was a result of a misconception that opium consump-
tion might reduce the adverse impacts of CVDs [15]. The 
effects of opium use on the cardiovascular system have 
been mediated by some endogenous ligands such as opi-
oid peptides [16]. Although, some people still assume 
that opium can be an alternative medication for car-
diovascular risk factors, especially diabetes [13], several 
studies showed that opium addiction increased the lev-
els of homocysteine that in turn results in the increased 
risk of CVDs in addicted population [17, 18]. Also, some 
other studies indicated that opium addiction is a risk fac-
tor for CVDs [19, 20].
The purpose of the present study was to investigate the 
relation of the duration and route of opium consump-
tion with ischemic heart diseases (IHD) and myocardial 
infarction (MI) CVDs.
Methods
Study design and patient selection
This cross-sectional study was conducted on participants 
of Rafsanjan cohort study (RCS); as a part of the prospec-
tive epidemiological research studies in IrAN (PERSIAN) 
[21], launched in August 2015 in Rafsanjan, a region in 
south east of Iran. Study population was selected via 9990 
sampling that had complete habit history [22]. Study 
inclusion criterion was the age range of 35–70 years 
(male or female). Study protocol was designed accord-
ing to the Persian cohort study and was approved by the 
Ethics Committee of Rafsanjan University of Medical Sci-
ences (Ethical codes: ID: IR.RUMS.REC.1399.081).
Data collection
All participants underwent a standardized interview to 
completely validated questionnaires containing questions 
on demography, socioeconomic status, smoking behav-
ior, opium use, alcohol consumption, history of disease, 
blood pressure, body mass index (BMI) and physical 
activity. Questionnaires were validated in the PERSIAN 
cohort study [21]. In this study, opium use was defined 
as self-reported use of opium. Subjects were divided into 
two groups of opium non-users (ONUs = 7612 subjects), 
opium users (OUs = 2378 subjects) [22].
CVD prevalence was assessed using self-reported 
information from the medical history questionnaire. 
Prevalent CVDs was defined as IHD and MI based on the 
self-reporting of the participants that a doctor told them 
they had angina, a myocardial infarction or reported 
undergoing coronary bypass surgery, balloon angioplasty 
or stent placement in coronary arteries [22].
Fasting serum total cholesterol, high density lipopro-
tein cholesterol (HDL cholesterol), low density lipo-
protein cholesterol (LDL cholesterol), S.G.O.T (AST), 
S.G.P.T (ALT), alkaline phosphatase, and triglycerides 
were measured using a CPALS analyzer (Coultronics, 
Margency, France) at the Central Laboratory in Cohort 
center.
Exposure and other covariate assessment
To assess opium use, we used a structured questionnaire 
in which detailed questions about age at the time of start-
ing opium use, amount and frequency of use (e. g. how 
many days a week in the case of weekly use), administra-
tion routes, opium types, and age the time of quitting for 
those who had quitted opium use. Routes of adminis-
tration included opium smoking and oral consumption. 
Opium types included teriak, Sukhteh, and Shireh. Teriak 
is a sticky paste which is prepared after air-drying the 
raw opium [23, 24]. Sukhteh is a black dry residue which 
sticks to the opium pipe after smoking Teriak. Sukhteh is 
then scraped from the pipe and can be ingested. Shireh 
is a refined product of opium which is often obtained by 
boiling a combination of raw opium and Sukhteh in water 
and filtering the mixture several times. Heroin is another 
product obtained from opium [23, 24]. However, its use 
among the participants of this cohort was rare, so heroin 
use was not evaluated in this study.
Statistical analyses
The chi-square test was used to analyze categorical vari-
ables across opium use categories. t -test was used to 
compare continuous variables among the groups. Logis-
tic regression models were used to investigate the rela-
tionships between opium use and the prevalence of IHD 
and MI. Confounders were identified using a causal dia-
gram (Additional file 1: Figure 1) [25, 26]. Based on sub-
ject matter knowledge and the relevant epidemiological 
literature, these confounders were sequentially entered 
into models according to their hypothesized strengths of 
association with opium use and IHD and MI. To reach 
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this goal, separate models at bivariate level were run to 
obtain variables associated with IHD and MI. After-
wards, variables with a p-value < 0.2 were considered for 
multivariate analysis [26]. Adjusted model 1 included 
basic sociodemographic characteristics (age, gender 
and education years) considered to be the most strongly 
related to both opium use and IHD and MI. Adjusted 
model 2 adjusted for lifestyle confounding variables 
(tobacco smoking, alcohol drinking) and physical activ-
ity level in addition to the sociodemographic character-
istics, to additionally confound opium use – IHD and MI 
associations. Adjusted model 3 included all variables in 
adjusted model 2 and additionally included hypertension, 
hypercholesterolemia, body mass index and diabetes 
mellitus, triglycerides, LDL cholesterol, HDL cholesterol, 
S.G.O.T (AST), S.G.P.T (ALT), and alkaline phosphatase. 
As these were hypothesized to be potential intermediates 
on the causal pathways that could explain opium use – 
IHD and MI relationships. In all models, variables of age, 
education years, hypercholesterolemia, body mass index 
(BMI) and, triglycerides, LDL cholesterol, HDL choles-
terol, S.G.O.T (AST), S.G.P.T (ALT), alkaline phosphatase 
were entered continuously. Also, for current users, dura-
tion of use was categorized into quintiles to test for dose-
response relationships. Also, the data were analyzed 
by routes of administration of opium used. Notably, for 
assess the association between opium consumption and 
the CVDs, we excluded individuals who reported opium 
use after their illness. Finally, we excluded 38 patients (31 
men and 7 female) who had started opium consumption 
after their illness.
Since opium use is categorized as stigmatized and 
sensitive behaviors, in this study some degree of non-
differential misclassification is probable as a result of 
misreporting or recall bias. So, we performed a simple 
bias analysis, one of the quantitative bias analysis meth-
ods, and compared the result of this analysis with that of 
the conventional result, to determine the direction and 
magnitude of the misreporting bias [27].
To determine the bias parameters (sensitivity and spec-
ificity of self-reported opium use), the results obtained 
from an internal validity study can be used. However, 
when the resources to perform an internal validation 
study are not available, previously-published validation 
studies which are applicable to the obtained data should 
be used. Finally, in the case of the existence of no relevant 
published data, the researchers have to use their experi-
ence and estimate the classification parameters.
Since no internal validation study has been performed 
in this population to assess the self-reporting of opium 
use, we used the results of an external validation study 
[28] and guess based on the existing conditions [22] to 
determine the bias parameters and perform simple bias 
analysis in order to correct the exposure measurement 
error (refer to applying quantitative bias analysis to epi-
demiologic data book for more details on how a simple 
bias analysis is performed) [27].
All analyses were conducted in State V.12. All p-values 
are two-sided, and p-values < 0.05 and 95% confidence 
intervals were considered as statistically significant.
We run a simple bias analysis, one of the quantitative 
bias analysis methods,
Results
In this study, 9990 participants in the baseline phase of 
the Rafsanjan adult cohort study were included. From 
this population, 4655 (46.60%) were male and 5335 
(53.40%) were female. Overall, the biological samples of 
9941 participants were collected on which laboratory 
measurements were carried out.
Table 1 shows the data collected from the opium users 
and non-users from the aspects of socio-demographic 
characteristics, lifestyle, personal habits, anthropomet-
ric measures, clinical risk factors and blood laboratory 
assessment. A participant is defined as opium user if he/
she reports using opium for at least once per week for 
6 months, prior to admission. The rate of opium use is 
relatively high in the RCS participants, especially in men 
(46.19% of men and 4.27% of women).
There are differences in some habits, measured clinical 
and laboratory indices among opium user and non-user 
participants (Tables  1 and  2). Educational attainment is 
lower in the opium users. Physical activity, HDL, alco-
hol consumption and cigarette smoking are consider-
ably higher in opium users. Hookah smoking is more 
common among the opium non-users. Abnormal serum 
levels of triglycerides, cholesterol, AST, and alkaline 
phosphatase are realized to be directly associated with 
opium using, whereas inverse association is observed 
between opium using and the abnormal serum levels of 
cholesterol, LDL cholesterol, and ALT. Furthermore, the 
frequency of hypertension, diabetes mellitus and obesity 
is significantly lower in the opium users.
Among all participants, 8.76% IHD and 2.98% MI were 
reported (Table 2). Prevalence of IHD and MI is consid-
erably more common among men (more than 2 times), 
especially in the age range of 55–64 years old. Both of the 
CVDs are more prevalent among opium users, cigarette 
smokers, overweighed people (BMI = 25–29.99) and sed-
entary people. Additionally, hypercholesterolemia and 
hypertension have direct association with the CVDs. 
As expected, consumption route and duration have sig-
nificant effects on the prevalence of MI and IHD. Longer 
consumption duration of opium has resulted in the 
higher incidence of both CVDs. In the case of consump-
tion route, MI and IHD are remarkably more common 
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Table 1 Selected characteristics of the Rafsanjan cohort participants (n = 9990)
Status of opium consumption
Characteristics All (n = 9990) Non-user (n = 7612) User (n = 2378) P-Value
Age ‑ yr. Mean ± SD 49.91 ± 9.56 49.33 ± 9.57 51.78 ± 9.31 < 0.001
Age‑ no. (%) < 0.001
 35–44 3466 (34.69) 2833 (37.22) 633 (26.62)
 45–54 3041 (30.43) 2290 (30.08) 750 (31.54)
 55–64 2759 (27.62) 1984 (26.06) 775 (32.59)
 ≥ 65 725 (7.26) 505 (6.63) 220 (9.25)
Gender‑ no. (%) < 0.001
 Female 5335 (53.40) 5107 (67.09) 228 (9.59)
 Male 4655 (46.60) 2505 (32.91) 2150 (90.41)
Education‑no. (%) < 0.001
 Illiterate 948 (9.50) 707 (9.30) 241 (10.13)
 Elementary 2547 (25.52) 1961 (25.79) 586 (24.64)
 Guidance school 2479 (24.84) 1688 (22.20) 791 (33.26)
 Diploma 2368 (23.73) 1845 (24.27) 523 (21.99)
 College 1639 (16.42) 1402 (18.44) 237 (9.97)
Physical activity Mean ± SD 38.77 ± 6.36 38.47 ± 5.59 8.29 ± 39.72 < 0.001
Alcohol consumption‑ no. (%) < 0.001
 yes 1351 (13.63) 469 (6.21) 882 (37.33)
 no 8561 (86.37) 7080 (93.79) 1481 (62.67)
Cigarette smoking‑no. (%) < 0.001
 Yes 2541 (25.66) 816 (10.82) 1725 (73.03)
 No 7362 (74.34) 6725 (89.18) 637 (26.97)
Hookah smoking‑ no. (%) < 0.001
 yes 1706 (17.22) 969 (12.84) 737 (31.20)
 No 8202 (82.78) 6577 (87.16) 1625 (68.80)
Hypertension‑ no. (%) < 0.001
 yes 2235 (22.50) 1823 (24.13) 412 (17.33)
 No 7698 (77.50) 5732 (75.87) 1966 (82.67)
Cholesterol‑ no. (%) < 0.001
 > 200(mg/dL) 4279 (43.04) 3404 (44.91) 875 (37.06)
 ≤ 200(mg/dL) 5662 (56.96) 4176 (55.09) 1486 (62.94)
 Mean ± SD 198.78 ± 41.89 200.66 ± 42.74 192.73 ± 38.43 < 0.001
Triglycerides‑ no. (%) < 0.001
 > 200(mg/dL) 2437 (24.53) 1779 (23.49) 658 (27.89)
 ≤ 200(mg/dL) 7496 (75.47) 5795 (76.51) 1701 (72.11)
 Mean ± SD 168.88 ± 109.22 165.86 ± 107. 28 178.57 ± 114.71 < 0.001
LDL cholesterol ‑ no. (%) < 0.001
 > 130(mg/dL) 2143 (21.56) 1718 (22.66) 425 (18.00)
 ≤ 130(mg/dL) 7798 (78.44) 5862 (77.34) 1936 (82.00)
 Mean ± SD 108.04 ± 30.49 109.23 ± 30.36 104.21 ± 30.61 < 0.001
HDL cholesterol ‑ no. (%) 0.029
 < 35(mg/dL) 42 (0.42) 26 (0.34) 16(0.68)
 ≥ 35(mg/dL) 9899 (99.58) 7554 (99.66) 2345 (99.32)
 Mean ± SD 57.90 ± 12.45 59.04 ± 12.67 54.24 ± 10.95 < 0.001
S.G.O.T (AST) ‑ no. (%) 0.329
 ≤ 39(U/L) 286 (2.88) 225 (2.97) 61 (2.58)
 > 39(U/L) 9655 (97.12) 7355 (97.03) 2300 (97.42)
 Mean ± SD 19.87 ± 11.81 19.72 ± 11.62 20.36 ± 12.38 0.022
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among opium smokers compared with those consume 
opium orally.
Table 3 presents the association of opium use with MI 
and IHD diseases, using the crude and three adjusted 
models. In the crude regression model, the odds of IHD 
(odds ratio (OR): 1.68, 95%CI 1.44 to 1.96) and MI (odds 
ratio (OR): 3.35, 95%CI 2.64 to 4.25) are almost Twice 
and triple greater among opium users compared with 
non-users. This association persisted after adjustment 
for confounders (adjusted model 2). The corresponding 
adjusted ORs calculated for opium users in compari-
son to non-users are 1.57 (95% CI 1.28 to 1.93) and 1.93 
(95% CI 1.42 to 2.63), respectively for IHD and MI dis-
eases. Adjusted model 3 includes all variables considered 
in adjusted model 2, plus hypertension, hypercholester-
olemia, BMI, diabetes mellitus, triglycerides, LDL, HDL, 
AST, ALT, and alkaline phosphatase which could act as 
potential intermediates in the causal pathways describ-
ing the relationship of opium use with IHD and MI dis-
eases. However, after adjusting for the variables (adjusted 
model 3), the obtained results showed no appreciable 
change and the mentioned association of IHD (odds 
ratio: 1.51, 95%CI 1.22 to 1.86) and MI (odds ratio (OR): 
1.79, 95%CI 1.31 to 2.45) with opium use was observed 
again. When the results were divided by quartile of con-
sumption duration in the current users, dose-response 
increases were observed with the highest odds ratios in 
the 4th quartile for MI and IHD (both p-values for trend 
< 0.001). Higher odds of IHD and MI were observed for 
the two main methods of opium consumption (oral and 
smoking), but oral administration had the highest odds 
ratio. In addition to adjusting for smoking, we performed 
a sensitivity analysis in smokers and non-smokers, since 
some of the increased odds of IHD and MI probably are 
driven from residual confounding from smoking or its 
interaction effects with opium use. We found that, use of 
opium alone (in the non-smokers) increased odds of IHD 
(adjusted odds ratio  (ORadj): 1.35, 95%CI 1.01 to 1.80) 
and MI (adjusted odds ratio  (ORadj): 1.70, 95%CI 1.09 to 
2.66), however, opium consumption accompanied with 
cigarette smoking (in the smokers) increased the odds of 
IHD (odds ratio: 1.80, 95%CI 1.28 to 2.53) and MI (odds 
ratio (OR): 1.97, 95%CI 1.24 to 3.12) beyond using opium 
alone. However, despite these increases, the interaction 
between opium consumption and cigarette smoking was 
not statistically significant (Additional file  2: eTable  1). 
Also, we investigated the interaction between opium use 
and gender, which was not statistically significant (Addi-
tional file  2: eTable  1). Additionally, to determine the 
direction and magnitude of the non-differential misre-
porting bias, we compared the results of simple bias anal-
ysis with those of the conventional results assuming that 
the specificity and sensitivity of the self-reported opium 
consumption in both healthy and patient groups are 90% 
(see other assumptions in the Additional file 3: eTable 2 
and Table 3).
The adjusted odds ratios for this bias about IHD and 
MI are 2.14 and 5.17, respectively. These Odds ratios 
were reported in the crude logistics model before adjust-
ing for this bias as 1.68 and 3.35, respectively. Based on 
Table 1 (continued)
Status of opium consumption
Characteristics All (n = 9990) Non-user (n = 7612) User (n = 2378) P-Value
S.G.P.T (ALT) ‑ no. (%) 0.052
 ≤ 39(U/L) 9130 (91.84) 6939 (91.54) 2191 (92.80)
 > 39(U/L) 811 (8.16) 641 (8.46) 170 (7.20)
 Mean ± SD 21.55 ± 15.37 21.74 ± 15.38 20.95 ± 15.32 0.030
Alkaline phosphatase‑ no. (%) < 0.001
 > 306 (IU/L) 972 (9.78) 663 (8.75) 309 (13.09)
 ≤ 306 (IU/L) 8969 (90.22) 6917 (91.25) 2052 (86.91)
 Mean ± SD 225.48 ± 66.81 222.05 ± 65.86 236.50 ± 68.66 < 0.001
BMI‑ no. (%) < 0.001
 < 25 2894 (28.97) 1813 (23.82) 1081 (45.46)
 25–29.9 4089 (40.94) 3213 (42.22) 876 (36.84)
 ≥ 30 3006 (30.09) 2585 (33.96) 421 (17.70)
 Mean ± SD 27.79 ± 4.99 28.40 ± 4.91 25.84 ± 4.76 < 0.001
Diabetes mellitus‑ no. (%) 0.005
 yes 1933 (19.46) 1517 (20.08) 416 (17.49)
 no 8000 (80.54) 6038 (79.92) 1962 (82.51)
BMI body mass index
Page 6 of 11Khalili et al. BMC Cardiovasc Disord            (2021) 21:2 
Table 2 Prevalence of myocardial infarction and ischemic heart diseases among the participants in the Rafsanjan cohort 
study (n = 9990)
Characteristic Myocardial infarction P -value Ischemic heart diseases P -value
Opium consumption‑ no. (%) < 0.001 < 0.001
 yes 154 (52.03) 313 (35.98)
 no 142 (47.97) 557 (64.02)
Duration of opium consumption ‑ no. (%)
 Non‑user 142 (47.97) < 0.001 557 (64.02) < 0.001
 ≤ 5 year 21 (7.1) 61 (7.01)
 6–10 year 21 (7.1) 52 (5.98)
 11/15 year 26 (8.78) 41 (4.71)
 16/20 year 35 (11.82) 56 (6.44)
 > 20 year 51 (17.23) 103 (11.84)
Route of opium consumption ‑ no. (%) < 0.001 < 0.001
 Smoking 140 (47.30) 282 (32.42)
 Oral consumption 14 (4.73) 31 (3.56)
Age cat‑ no. (%) < 0.001 0 (0.00) < 0.001
 35–44 18 (6.08) 56 (6.44)
 45–54 64 (21.62) 201 (23.10)
 55–64 157 (53.04) 433 (49.77)
 ≥ 65 57 (19.26) 180 (20.69)
Gender‑ no. (%) < 0.001 0.003
 Female 85 (28.72) 424 (48.74)
 Male 211 (71.28) 446 (51.26)
Education‑no. (%) < 0.001 < 0.001
 Illiterate 54 (18.24) 175 (20.11)
 Elementary 84 (28.38) 263 (30.23)
 Guidance school 54 (18.24) 180 (20.69)
 Diploma 62 (20.95) 158 (18.16)
 College 42 (14.19) 94 (10.80)
Physical activity. Mean ± SD 36.66 ± 5.28 < 0.001 37.18 ± 5.28 < 0.001
Alcohol consumption‑ no. (%) 0.012 0.645
 yes 55 (18.58) 114 (13.12)
 no 241 (81.42) 755 (86.88)
Cigarette smoking ‑no. (%) < 0.001 < 0.001
 yes 152 (51.35) 286 (32.91)
 no 144 (48.65) 583 (67.09)
Hookah consumption‑ no. (%) 0.060 0.065
 yes 63 (21.28) 130 (14.96)
 no 233 (78.72) 739 (85.04)
Hypertension‑ no. (%) < 0.001 < 0.001
 yes 119 (40.20) 440 (50.57)
 no 177 (59.80) 430 (49.43)
Cholesterol‑ no. (%) < 0.001 < 0.001
 > 200(mg/dL) 86 (29.25) 269 (31.10)
 ≤ 200 (mg/dL) 208 (70.75) 596 (68.90)
Triglycerides‑ no. (%) 0.224 0.824
 > 200 (mg/dL) 81(27.55) 215 (24.86)
 ≤ 200(mg/dL) 213 (72.45) 650 (75.14)
LDL cholesterol ‑ no. (%) 0.103 0.043
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this analysis (on condition of the accuracy of the val-
ues assigned to the bias parameters), percent biases, 
were − 22% for IHD and − 35% for MI, indicating that the 
odds ratio increased or, on the other words, there was 25 
and 35% error towards null before adjusting for this bias 
(see Additional file 4: eTable  4 for more details on con-
ducting a simple bias analysis).
Discussion
The present study is a crass-sectional study aimed at 
assessment of the association between opium use and 
cardiovascular diseases in the participants of the Rafsan-
jan Cohort Study, an area in the southeast of Iran with 
a relatively high prevalence of opium use. According to 
our findings, 23.81% of the Rafsanjani adult population 
(46.19% of men and 4.27% of women) reported opium 
use at least once per week for 6 months. The main finding 
of this study was that cardiovascular diseases were con-
siderably more common among opium users (even after 
adjusting for some potential confounding variables) com-
pared with non-users with a dose-response relationship. 
Our results on dose–response relationships between 
the risk of cardiovascular disease and duration of opium 
consumption strengthened the conclusion that opium 
use was directly associated with an increased risk of 
cardiovascular disease. This finding was consistent with 
those of similar studies. Niaki et  al. showed that opium 
consumption was a significant risk factor of MI with an 
adjusted odds ratio of 26.3 [9]. Sadeghian et al. presented 
the opium abuse as a major risk factor of ischemic heart 
disease [29]. In another study on 556 patients with MI, 
opium addiction was found in 19% of the patients versus 
2.8% of the general population [19]. In a similar study 
on patients with coronary artery disease (CAD) con-
firmed with angiography, an association between opium 
addiction and the development of CAD was found in the 
male patients [30]. Another angiographic study on 2405 
patients, demonstrated the higher prevalence of vascular 
involvement in addicts in comparison to non-addict peo-
ple [29]. Also, a review study came to the conclusion that 
opium consumption may be associated with high risk of 
the other chronic diseases, such as cardiovascular dis-
eases [31]. In accordance with this finding, Hosseini et al. 
observed a dose-response relationship between dose of 
opium and the Gensini score (β = 0.27, p = 0.04), after 
adjustment for potential confounders [32]. As expected, 
in all routes of opium consumption, there was a direct 
relation between opium use and cardiovascular disease; 
meantime, another result of our study was that oral 
administration of opium was associated with higher odds 
of cardiovascular disease. This finding was in accordance 
with the report of Mohammadi et  al. showed that oral 
Table 2 (continued)
Characteristic Myocardial infarction P -value Ischemic heart diseases P -value
 > 130 (mg/dL) 52 (17.69) 163 (18.84)
 ≤ 130 (mg/dL) 242 (82.31) 702 (81.16)
HDL cholesterol ‑ no. (%) 0.001 0.069
 < 35 (mg/dL) 5 (1.70) 7 (0.81)
 ≥ 35 (mg/dL) 289 (98.30) 858 (99.19)
S.G.O.T (AST) ‑ no. (%) 0.046 0.617
 ≤ 39 (U/L) 280 (95.24) 838 (96.88)
 > 39 (U/L) 14 (4.76) 27 (3.12)
S.G.P.T (ALT) ‑ no. (%) 0.530 0.034
 ≤ 39 (U/L) 273 (92.86) 811 (93.76)
 > 39 (U/L) 21 (7.14) 54 (6.24)
Alkaline phosphatase‑ no. (%) 0.004 0.007
 > 306 (IU/L) 43 (14.63) 107 (12.37)
 ≤ 306 (IU/L) 251 (85.37) 758 (87.63)
BMI‑ no. (%) 0.065 0.137
 < 25 101 (34.12) 229 (26.32)
 25–29.9 121 (40.88) 359 ( ( (41.26)
 ≥ 30 74 (25.00) 282 (32.41)
Diabetes mellitus‑ no. (%) < 0.001 < 0.001
 yes 124 (41.89) 343 (39.43)
 no 172 (58.11) 527 (60.57)
BMI body mass index
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opium administration accelerated atherosclerosis forma-
tion in hypercholesterolemia rabbits [33]. Hosseini et al. 
observed no significant differences between the routes of 
opium administration (inhalation vs. oral) regarding the 
extent and severity of CAD [32]. Since several reports 
suggested lead poisoning in Iranian opium addicts, it is 
possible that lead in opium increases the risk of CVDs in 
opium users. The opium adulterated with lead is a new 
source of lead poisoning in Iran, where the opium abuse 
is relatively frequent [6]. Chemical analysis of the opium 
has confirmed this claim. Generally, consumption of con-
taminated drugs have been reported as a source of expo-
sure to toxins such as arsenic and lead [34]. Although, 
the mechanisms of the effects of opium administration 
on cardiovascular diseases are not precisely known and 
required to be further investigated, a related research 
has examined the level of blood lead and mortality risk 
in the general population of the United States using 
mortality follow-up data for participant ≥40 years old 
from NHANES III. The result of this large cohort study 
Table 3 Association of opium consumption with myocardial infarction and Ischemic heart diseases (n = 9952*)
* Excluding 38 individuals who have started opium after their illness
a The baseline model is stratified on the status of opium consumption
b The adjusted model 1 is adjusted for confounding variables age (continuous variable), gender (male/ female) and education years (continuous variable)
C The adjusted model 2 has additional adjustment for confounding the variables related to lifestyle (cigarette smoking, alcohol drinking and hookah consumption) 
and physical activity level (continuous variable)
d The adjusted model 3 has additional adjustment for hypertension (yes/no), hypercholesterolemia (continuous variable), body mass index (continuous variable) and 
diabetes mellitus (yes/no), Triglycerides (continuous variable), LDL cholesterol (continuous variable), HDL cholesterol (continuous variable), S.G.O.T (AST) (continuous 
variable), S.G.P.T (ALT) (continuous variable), Alkaline phosphatase (continuous variable)
Crude model Adjusted model 1 Adjusted model 2 Adjusted model 3
OR (95%Ci)a OR(95%Ci)b OR (95%Ci)c OR(95%Ci)d
Ischemic heart diseases
 Opium consumption
 yes 1.68 (1.44–1.96) 1.51 (1.24–1.82) 1.57 (1.28–1.93) 1.51 (1.22–1.86)
 no 1 1 1 1
Duration of opium consumption
 Non‑user 1 1 1 1
 ≤ 5 year 0.95 (0.66–1.36) 0.94 (0.64–1.36) 0.97 (0.66–1.42) 0.84 (0.57–1.25)
 6–10 year 1.15 (0.83–1.60) 1.23 (0.87–1.75) 1.29 (0.90–1.86) 1.28 (0.89–1.85)
 11/15 year 1.66 (1.18–2.33) 1.86 (1.28–2.70) 1.99 (1.35–2.94) 2 (1.33–2.99)
 16/20 year 1.90 (1.42–2.55) 1.90 (1.37–2.64) 2.07 (1.46–2.92) 2.11 (1.48–3.01)
 > 20 year 2.74 (2.18–3.45) 1.82 (1.39–2.37) 1.94 (1.45–2.60) 1.99 (1.47–2.70)
Route of opium consumption
 Non‑user 1 1 1 1
 Smoking 1.60 (1.37–1.87) 1.45 (1.20–1.76) 1.50 (1.22–1.85) 1.47 (1.18–1.82)
 Oral consumption 3.30 (2.12–5.13) 2.33 (1.46–3.74) 2.46 (1.50–4.02) 2.30 (1.36–3.89)
Myocardial infarction
Opium consumption
 yes 3.35 (2.64–4.25) 2.07 (1.56–2.73) 1.93 (1.42–2.63) 1.79 (1.31–2.45)
 no 1 1 1 1
Duration of opium consumption
 Non‑user 1 1 1 1
 ≤ 5 year 1.55 (0.89–2.71) 1.19 (0.67–2.11) 1.14 (0.64–2.04) 0.98 (0.54–1.79)
 6–10 year 1.69 (1–2.85) 1.22 (0.70–2.12) 1.19 (0.67–2.08) 1.20 (0.70–2.07)
 11‑15 year 4.10 (2.64–6.37) 3.07 (1.91–4.93) 2.97 (1.80–4.89) 2.92 (1.76–4.84)
 16–20 year 4.67 (3.18–6.86) 3.064 (2.01–4.67) 3.04 (1.94–4.76) 3.11(1.97–4.89)
 > 20 year 5.08 (3.65–7.08) 2.29 (1.57–3.33) 2.20 (1.45–3.35) 2.15 (1.41–3.28)
Route of opium consumption
 Non‑user 1 1 1 1
 Smoking 3.23 (2.53–4.12) 2.02 (1.52–2.68) 1.89 (1.38–2.60) 1.77 (1.30–2.42)
 Oral consumption 5.54 (2.99–10.28) 2.81(1.47–5.35) 2.52 (1.28–4.95) 2.12 (1.04–4.30)
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indicated the association of increased risk of death from 
all causes, cardiovascular disease, and cancer with the 
elevated levels of blood lead. Especially for mortality due 
to CVDs, there was also a pattern of the increasing risk 
of the disease with the increasing level of blood lead [35]. 
Lead-related atherosclerosis could be elucidated using 
several mechanisms, including increases in blood pres-
sure, impairment of renal function, induction of oxida-
tive stress, inflammation, and endothelial dysfunction 
[36]. Adequate mechanistic studies have not been per-
formed on the effects of chronic use of opium, so further 
research is needed to describe the possible mechanisms 
and check the accuracy of the findings. At conclude, the 
methods of opium consumption may fewer is considered, 
while could hence the risk of CVD.
Furthermore, our supplementary analysis showed that 
opium consumption accompanied by cigarette smoking 
was associated with higher odds of IHD and MI, com-
pared with using opium alone. However, the interaction 
between opium consumption and cigarette smoking was 
not statistically significant. Also, we investigated the 
interaction between opium use and gender, which was 
not statistically significant, too.
This study has strengths and limitations. One of the 
main strengths of our study is its population-based 
nature with a large sample size, extensive data collection 
for the exposure of interest (opium) and potential con-
founders (e.g. cigarette smoking, age, sex and etc.).
However, the study has some limitations too. For 
instance, it is possible that a number of people have not 
completely reported their status of opium consumption. 
On the other hand, there may be also some degrees of 
misclassification due to self-reporting and recall biases. 
According to the results of various studies, data of opium 
use based on self-reporting may cause misreporting when 
compared with biological tests. So, this type of studies is 
susceptible to measurement errors such as self-reporting 
bias, which possibly leads to some deviations from real-
ity (incidence of bias in estimates) [37–41]. However, the 
amount of this self-reporting bias depends on sex, age, 
type of substances, geographical area and the under-
study population. It can be resulted from the differences 
in social and cultural beliefs for various individuals and 
regions [42–44]. Fortunately, we believe that the validity 
of the data on opium use in our population is relatively 
high, probably because opium consumed in this popula-
tion with lower social stigma. In a similar study, Abnet 
et al. reported a high rate of sensitivity of opium use in a 
population among Turkmen in the north of Iran [28]. It 
has been demonstrated that the Turkmen population, use 
opium as a traditional medicine with low social stigma.
Although, in our study the results of simple bias analy-
sis showed that the direction and magnitude of this bias 
are probably towards null and the adjusted odds ratio 
for this bias about IHD and MI is stronger than that of 
the conventional result, the accuracy of the results of 
this model is strongly influenced by the accuracy of bias 
parameters [27]. Since no internal validation study has 
been performed in this population to assess the self-
reporting of opium use, we used the results of an external 
validation study [28] and guess based on existing condi-
tions [22] to determine the bias parameters that may be 
not accurate. Therefore, it is suggested to conduct an 
internal validation study on our population to examine 
the magnitude and direction of this bias more accurately.
Although, we excluded the patients who reported 
opium use after their illness, it is possible that some par-
ticipants have mistakenly reported their age of start of 
opium consumption and/or the age of their illness diag-
nosis, as a result of recall bias. On the other words, they 
have started opium consumption after development of 
the CVDs to suppress angina symptom and so, opium 
use is not a risk factor. Accordingly, it is suggested that 
this relationship be reconsidered in the follow-up phase 
of this prospective study.
Conclusions
In conclusion, our results shows that opium consumption 
not only has no ameliorating effect on CVDs; it may have 
some adverse effects on these diseases. Therefore, people 
should be informed about the hazardous effects of opium 
consumption on cardio-metabolic diseases.
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